Wockhardt Limited has announced that the U. S. Food and Drug Administration ('USFDA') has carried out inspection of Bioequivalence Centre located at R&D Centre, Aurangabad during which Bioequivalence studies of Tamsulosin 0.4mg capsules and Metoprolol Tartrate 200mg ER tablets were audited. At the end of inspection, there was Nil observation (i.e. zero 483 observation), signifying that best practices were followed, in compliance to applicable regulations. This outcome would lead approvals of ANDAs in pipeline for which Bioequivalence studies are being or will be done in the said Centre.
Shares of WOCKHARDT LTD. was last trading in BSE at Rs.449.25 as compared to the previous close of Rs. 447.1. The total number of shares traded during the day was 228876 in over 2600 trades.
The stock hit an intraday high of Rs. 454 and intraday low of 447.5. The net turnover during the day was Rs. 103239344.